Skip to content

Lisa Harding

5 papers in the library · 14 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Contemporary Clinical Trials March 2, 2026 Samuel T. Wilkinson, Sandhya Prashad, Rachel Dalthorp et al. 1 citation

Ketamine is a powerful and rapid-acting antidepressant but has no regulatory authorization for any psychiatric illness. The S-enantiomer of ketamine, esketamine, was approved by the FDA in 2019 as adjunctive therapy for treatment-resistant depression. Substantial controversy exists as to whether there is a significant clinical difference between intravenous (IV) ketamine racemate and intranasal...

DOI: 10.1016/j.cct.2026.108273 (opens in new tab) Ketamine Humans Antidepressive agents Administration, intranasal +6

Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.

Clinical Therapeutics March 1, 2025 Lisa Harding, Maryia Zhdanava, Amanda Teeple et al. 3 citations

Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. Data on health care resource use (HRU) and costs among patients with MDSI initiated on esketamine nasal spray relative to traditional treatments are limited. This study sought to describe HRU and medical costs of patients with MDSI initiated on...

DOI: 10.1016/j.clinthera.2024.12.006 (opens in new tab) Full text (opens in new tab) Acute care Antidepressant Health care costs Suicidal ideation +5

Music mindfulness acutely modulates autonomic activity and improves psychological state in anxiety and depression.

Frontiers in Neuroscience 2025 Christine Ramirez, Gertrude Asumpaame Alayine, Cyril Selase Kwaku Akafia et al. 3 citations

Anxiety and depression reduce autonomic system activity, as measured by Heart Rate Variability (HRV), and exacerbate cardiac morbidity. Both music and mindfulness have been shown to increase HRV, and clinical approaches incorporating these interventions show promise as effective treatments for symptoms of anxiety and depression. Music mindfulness, which combines music listening with mindfulness...

Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.

Current Medical Research and Opinion September 1, 2024 Lisa Harding, Maryia Zhdanava, Aditi Shah et al. 2 citations

In the United States (US), prescription drug coverage is subject to prior authorization (PA) criteria, which may vary between health plans and may exceed drug label requirements. This study aimed to characterize profiles and treatment history of patients with treatment-resistant depression (TRD) who initiated esketamine nasal spray, by stringency of their health plans' PA criteria relative to...

DOI: 10.1080/03007995.2024.2380743 (opens in new tab) Full text (opens in new tab) Antidepressant Antipsychotic Insurance coverage Prior authorization +5

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States.

Drugs - real world outcomes June 1, 2024 Lisa Harding, Kruti Joshi, Maryia Zhdanava et al. 5 citations

This study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (TRD) who completed induction treatment with esketamine nasal spray in the United States (US). Per label, induction is defined as administration twice a week for 4 weeks, after which maintenance is started on a weekly basis for 4 weeks, and thereafter,...

DOI: 10.1007/s40801-024-00425-2 (opens in new tab) Full text (opens in new tab) Depression treatment Healthcare costs Esketamine therapy Mental health economics +1